Investigational drug · Phase 3
NNC6019-0001
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Transthyretin Amyloid Cardiomyopathy (ATTR CM).
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
3
Any phase or sponsor naming "NNC6019-0001"
First trial start
2022
Aug 2, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NNC6019-0001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Approved drugs for the same conditions: Transthyretin amyloidosis · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "NNC6019-0001" as an intervention, largest first.
- CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) AmyloidosisPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07207811 · 1,280 participants (planned) · Start Oct 2, 2025 · Primary completion Jun 29, 2029
Drug: NNC6019-0001; Placebo (NNC6019-0001) · For: Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 299 sites in all
- A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) AmyloidosisPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05442047 · 105 participants · Start Aug 2, 2022 · Primary completion Feb 17, 2025
Drug: NNC6019-0001; Placebo (NNC6019-0001) · For: Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Sites: Phoenix, Arizona; Beverly Hills, California; Stanford, California · 39 sites in all
- A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin AmyloidosisActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06260709 · 88 participants (planned) · Start Feb 20, 2024 · Primary completion Feb 29, 2028
Drug: NNC6019-0001 · For: Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Sites: Phoenix, Arizona; Los Angeles, California; Stanford, California · 38 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novo Nordisk.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.